P/S Ratio: The Valuation Metric That Works When P/E Does Not
For unprofitable growth companies, P/E is meaningless. The price-to-sales ratio fills the gap. Here is when to use it, how to interpret it, and where it breaks down.
The Problem With P/E for Growth Stocks
Try to calculate a P/E ratio for a company that loses money. You can't. Or rather, you can, but the result is negative and tells you nothing useful. A P/E of -47x doesn't mean the stock is cheap or expensive. It just means the company isn't profitable yet.
This is a real problem, because some of the most important investment opportunities are in companies that haven't turned profitable. Early-stage SaaS companies reinvesting in growth. Biotech firms spending on R&D before their first drug hits the market. Disruptors burning cash to capture market share.
If you only use P/E, you're blind to the valuation of these companies. That's where P/S comes in.
What P/S Measures
Price-to-Sales (P/S) = Market Capitalization / Trailing Twelve-Month RevenueOr equivalently: P/S = Stock Price / Revenue Per Share
Every company that generates revenue has a calculable P/S ratio, regardless of profitability. Revenue is also harder to manipulate than earnings, which makes P/S a more stable metric. Companies can play games with depreciation, stock-based compensation, and one-time charges to swing EPS around. Revenue is revenue.
A P/S of 10x means investors are paying $10 for every $1 of annual revenue. Is that expensive? It depends entirely on the industry, the growth rate, and the margin profile.
When P/S Is the Right Metric
High-growth SaaS companies. Most SaaS businesses prioritize revenue growth over profitability in their early years. Investors care about the growth rate and the path to margins, not current earnings. Snowflake, CrowdStrike, and Datadog all traded at double-digit P/S multiples long before they became consistently profitable. The P/S ratio let investors compare their valuations even when P/E was undefined. Biotech and pharma. A biotech company in Phase 3 trials might have minimal revenue and deep losses. If it has any commercial products, P/S captures how the market values that revenue base relative to the pipeline optionality. Turnaround stories. Companies restructuring toward profitability often have depressed or negative earnings but stable revenue. P/S gives you a baseline for what you're paying for the top line while the bottom line is in flux. Cyclical businesses at trough earnings. During a cyclical downturn, earnings can collapse temporarily while revenue stays more resilient. P/S shows the through-cycle valuation better than a P/E that might be 200x because earnings hit a temporary trough.How to Interpret P/S
Unlike P/E, there's no universal "fair" P/S number. Context is everything:
- Software/SaaS: 5-15x is typical for growing companies. Over 20x signals very high growth expectations.
- Retail/Consumer: 0.5-2x is normal. These are low-margin businesses.
- Industrials: 1-3x is typical.
- Biotech with commercial products: Varies wildly, 3-30x depending on pipeline.
The Limitations
P/S has real blind spots:
It ignores profitability entirely. A company burning $500M per year and a company earning $500M per year can have the same P/S ratio. Revenue alone doesn't tell you if the business model works. It ignores capital structure. P/S uses market cap, which only reflects equity value. A heavily indebted company will look cheaper on P/S than it should. That's why EV/Revenue (enterprise value / revenue) is often a better choice, since it accounts for debt and cash. Revenue quality matters. $100M in recurring SaaS subscriptions is worth more than $100M in one-time project revenue. P/S treats them the same.StockResearch Auto-Suggests P/S
When you look up a company on StockResearch and its P/E ratio is unavailable (because earnings are negative), we automatically highlight P/S and EV/Revenue as alternatives. No need to figure out which metric applies. The tool adapts to the company's financial profile.
You can also chart P/S ratios over time and overlay peers, the same way you would with P/E. Watch how a company's revenue multiple compresses as it scales and approaches profitability.
Try It
Compare the P/S ratios of two growth stocks to see how the market values their revenue differently:
Open the Multiples Tab on StockResearchThis post is for informational purposes only and does not constitute financial advice. Valuation multiples should be considered alongside other financial metrics and qualitative factors. Past valuation levels do not predict future returns.